川地34
髓系白血病
干细胞
CD33
骨髓
白血病
CD38
川东北117
髓样
CD44细胞
癌症研究
医学
病理
免疫学
肿瘤科
内科学
生物
细胞
细胞生物学
遗传学
作者
Wendelien Zeijlemaker,Angèle Kelder,Yvonne J.M Oussoren-Brockhoff,Willemijn J. Scholten,Alexander N. Snel,Dennis Veldhuizen,Jacqueline Cloos,G.J. Ossenkoppele,Gerrit Jan Schuurhuis
出处
期刊:Leukemia
[Springer Nature]
日期:2015-09-16
卷期号:30 (2): 439-446
被引量:109
摘要
Relapses after initial successful treatment in acute myeloid leukemia are thought to originate from the outgrowth of leukemic stem cells. Their flow cytometrically assessed frequency is of importance for relapse prediction and is therefore assumed to be implemented in future risk group profiling. Since current detection methods are complex, time- and bone marrow consuming (multiple-tubes approach), it would be advantageous to have a broadly applicable approach that enables to quantify leukemia stem cells both at diagnosis and follow-up. We compared 15 markers in 131 patients concerning their prevalence, usefulness and stability in CD34+CD38− leukemic stem cell detection in healthy controls, acute myeloid leukemia diagnosis and follow-up samples. Ultimately, we designed a single 8-color detection tube including common markers CD45, CD34 and CD38, and specific markers CD45RA, CD123, CD33, CD44 and a marker cocktail (CLL-1/TIM-3/CD7/CD11b/CD22/CD56) in one fluorescence channel. Validation analyses in 31 patients showed that the single tube approach was as good as the multiple-tube approach. Our approach requires the least possible amounts of bone marrow, and is suitable for multi-institutional studies. Moreover, it enables detection of leukemic stem cells both at time of diagnosis and follow-up, thereby including initially low-frequency populations emerging under therapy pressure.
科研通智能强力驱动
Strongly Powered by AbleSci AI